Nathalie Hafner

Ms. Nathalie Hafner

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Applied Sciences
Verified
Journal Article
Open access
PDF file
NHNathalie Hafner
Nathalie Hafner
NSNazanin Nematzadeh Somehsaraei
Nazanin Nematzadeh Somehsaraei
MHMaximilian Nicolas Honemann
Maximilian Nicolas Honemann
HDHendrik Dietz
Hendrik Dietz
DWDirk Weuster-Botz
Dirk Weuster-Botz
Large quantities of artificial single-stranded DNA (ssDNA) with user-defined sequences are increasingly required to exploit the potential of DNA nanotechnology. Cross-contamination-free ssDNA production can be achieved using Escherichia coli with an optimized helper plasmid in high-cell-density cultivation via the secretion of phagemid particles containing ssDNA with user-defined sequences. In our study, we aimed to reduce the number of phagemid particles for the initiation of ssDNA production. We tested different infection densities, ranging from a multiplicity of infection (MOI) of 10−6–10−2 tfu cfu−1 at the start of the initial batch phase in a 2.5 L stirred tank bioreactor. A MOI of 10−3 tfu cfu−1 was the best compromise between process time and ssDNA concentration. Early initiation of ssDNA production with low MOI reduced the number of phagemid particles by a factor of 250,000. The early infection strategy was successfully scaled up to the 25 L scale, resulting in ssDNA concentrations of >100 mg L−1 within a process time of one day. Transferring the infection strategy to a 1000 L scale gained 65 mg L−1 ssDNA because of incomplete initial infection. The versatility of the early infection strategy was further proven with a second prolonged, user-defined ssDNA sequence.

5 August 2026 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
PDF file
NHNathalie Hafner
Nathalie Hafner
WWWiebke Winkler
Wiebke Winkler
MHMaximilian Nicolas Honemann
Maximilian Nicolas Honemann
HDHendrik Dietz
Hendrik Dietz
DWDirk Weuster-Botz
Dirk Weuster-Botz
Single‐stranded DNA (ssDNA) solutions are promising innovations shaping the future of genetic research and medical therapies. In principle, biotechnological mass production of ssDNA can be achieved using Escherichia coli in a high‐cell density fed‐batch process by secreting phagemid particles derived from the filamentous M13 bacteriophages. However, the production of user‐defined ssDNA enveloped in phagemid particles results in partial lysis of E. coli cells, affecting their sedimentation behavior, thereby complicating cell separation in disc‐stack centrifuge processing. We have demonstrated that complete cell removal can be achieved using tangential flow microfiltration, although the M13 bacteriophage‐derived particles, due to their 900 nm length and 6 nm diameter, pose a challenge for tangential flow filtration. Endonuclease‐mediated nonspecific DNA digestion improved cross‐flow microfiltration, enabling phagemid particle transmission above 90% without degrading the ssDNA product, which remained protected within the phagemid particle's protein shell. In a second cross‐flow ultrafiltration, the M13‐derived particles were concentrated by a factor of 10 and washed by diafiltration. A 750 kDa cut‐off was found to be appropriate for ultrafiltration, quantitatively retaining the phagemid particles during concentration and diafiltration. With this step, the previously used addition of polyethylene glycol 8000 and NaCl for phagemid particle agglomeration and precipitation can be completely replaced, thereby making this new scalable purification process more suitable for pharmaceutical production.